Assessment of the impact of psychobiotics supplementation on the occurrence of depression and anxiety disorders in people with a history of Covid-19 disease

Not Applicable

Recruiting

• Conditions: COVID19; F41.2; Mixed anxiety and depressive disorder

• Registration Number: DRKS00026955
• Lead Sponsor: Department of Pediatric Gastroenterology and Metabolic Diseases; Poznan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-10-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Patient-reported postovid depression or anxiety changes (score = 12 on the HADS-anxiety subscale (HADS-A) and / or on the HADS-depression subscale (HADS-D),
- consent to participate in the study

Exclusion Criteria

- pregnancy,
- severe coexisting diseases (liver cirrhosis, portal hypertension, renal failure, neoplastic diseases, diabetes, connective tissue diseases) and menopause,
- previously (pre-covid) diagnosed mental illnesses, psychiatric treatment,
- taking psychotropic drugs, stimulating / activating dietary supplements (ginger, guarana, ginseng, melatonin), drugs

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
feeling anxiety and depression (HSCL-90, Hopkins Symptom Checklist)

Secondary Outcome Measures

Name	Time	Method
cortisol concentration<br>composition of the intestinal microbiota<br>the concentration of short chain fatty acids in the stool<br>assessment of the concentration of inflammatory cytokines<br>psychological tests HADS, GAD-7